Table 2.
The relationship between other cancer treatment and the prevalence of COVID 19
| Cancer | Renal cell carcinoma | Bladder cancer | Germ cell tumor | Soft tissue sarcoma | Head and neck cancer | Thyroid cancer | Ovarian cancer | Ewing family tumor |
|---|---|---|---|---|---|---|---|---|
| Number Patients | 6 | 5 | 4 | 8 | 6 | 4 | 8 | 4 |
|
Stage I Stage II Stage III Stage IV |
Locally advanced 3 Metastatic 4 |
Stage II–III | 4 |
Metastatic MTC: 3 Metastatic Follicular Carcinoma: 1 |
Stage III: 3 Metastatic: 5 |
|||
| Treatment |
INf Sunitinib |
CHT | CHT | CHT |
CHT Cetuximab |
Sorafinib Zometa |
CHT | |
|
COVID 19 RT-PCR |
0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Suspicious in HRCT SCAN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Live | 6 | 6 | 4 | 8 | 4 | 4 | 8 | 4 |
| Death due COVID 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Progression of malignancy | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Treatment method | Q3 weeks | Q3 weeks | Q3 weeks | Q3 weeks | Daily | Q3 weeks | Q3 weeks |
MTC medullary thyroid carcinoma B, CHT chemotherapy, Q3 weeks once every 3 week